A Phase Ib Open Label, Expansion Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast and Liver Tumours.

Trial Profile

A Phase Ib Open Label, Expansion Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast and Liver Tumours.

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Oct 2015

At a glance

  • Drugs CUDC 101 (Primary)
  • Indications Breast cancer; Gastric cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 17 May 2012 Results will be presented at the 48th Annual Meeting of the American Society of Clinical Oncology, according to a Curis media release.
    • 17 May 2012 New source identified and integrated (M.D. Anderson Cancer Center 2010-0483).
    • 17 May 2012 Planned number of patients changed from 40 to 50 as reported by M.D. Anderson Cancer Center record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top